If you've been reading about medications for alcohol use disorder and landed on acamprosate after hearing more about naltrexone, you're asking exactly the right follow-up question. These two drugs get lumped together constantly, but they work through entirely different mechanisms, suit different patients, and have different evidence profiles. Understanding that distinction is the whole game when it comes to choosing between them.

Acamprosate — brand name Campral — received FDA approval in 2004. Its job is specific: helping people who have already stopped drinking stay stopped. If you or someone you care about has just completed alcohol detox and is trying to protect that early abstinence, acamprosate is the medication most directly designed for that window.

How does acamprosate actually work in the brain?

Chronic heavy drinking rewires the brain's excitatory signaling system. Alcohol suppresses glutamate — the brain's primary "accelerator" neurotransmitter — and the brain compensates by ramping up glutamate receptors, particularly NMDA-type receptors. When alcohol is removed, that compensation is suddenly unmasked. The result is a state of glutamate overactivity: the brain is flooded with excitatory signals, producing the anxiety, restlessness, and craving that characterize early abstinence and push people back toward drinking [1]✓ Verified knowledgeMandaji et al. (2025) — Combination drugs treatment.

Acamprosate modulates NMDA-type glutamate receptors, dampening this post-withdrawal excitatory surge and helping restore neurochemical balance [2]✓ Verified knowledgeCostin et al. (2014) — Molecular neurologic responses. A magnetic resonance spectroscopy study found that acamprosate produced a highly significant suppression of the glutamate-to-creatine ratio in the anterior cingulate cortex of abstinent patients (F₁,₂₉ = 13.5, p < .001) — direct neuroimaging evidence of its central effect [3]✓ Verified knowledgeZastrozhin et al. (2019) — Pharmacogenetics alcohol addiction.

This mechanism is entirely different from naltrexone's. Naltrexone is a μ-opioid receptor antagonist — it blocks the reward signal that alcohol produces through the endorphin system. Acamprosate doesn't touch the opioid system at all. Different receptor system, different clinical target, different patient profile.

What does the research actually show?

The evidence base for acamprosate is built on some of the largest meta-analyses in AUD pharmacotherapy.

The Rösner et al. Cochrane systematic review synthesized 24 randomized controlled trials with 6,915 participants and found that acamprosate significantly reduces the risk of any drinking (RR 0.86, 95% CI 0.81–0.91; NNT 9.09) and significantly increases cumulative abstinence duration (mean difference 10.94 days, 95% CI 5.08–16.81) compared to placebo. Critically, diarrhea was the only side effect more frequent than placebo [4]✓ Verified knowledgeKampman et al. (2011) — Double blind placebo.

The Mann et al. meta-analysis of 17 RCTs (n = 4,087) found continuous abstinence rates at 6 months of 36.1% with acamprosate versus 23.4% with placebo — a relative benefit of 1.47 (95% CI 1.29–1.69, p < 0.001), with a number needed to treat of 7.5 at 12 months [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking. The Bouza et al. analysis corroborated this with an abstinence odds ratio of 1.88 (95% CI 1.57–2.25) [6]✓ Verified knowledgeBouza et al. (2004) — Efficacy safety naltrexone.

An NNT of 7–9 compares favorably to many widely used medications in chronic disease management. These are meaningful effect sizes, not marginal signals [4]✓ Verified knowledgeKampman et al. (2011) — Double blind placebo.

Why did some U.S. trials show no benefit?

Not every trial has been positive, and the discrepancy between European and U.S. results is worth understanding — because it tells you something important about who the drug works for.

Several U.S. trials, including a family medicine setting study and a Korean multicenter trial [7]✓ Verified knowledgeNamkoong et al. (2003) — Acamprosate korean alcohol, found no significant overall benefit over placebo. The Chick et al. UK multicenter trial similarly found no abstinence benefit [8]✓ Verified knowledgeChick et al. (2000) — United kingdom multicentre. The evidence points to several specific reasons:

• Who was recruited. Some U.S. trials recruited through advertisement in primary care settings [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking. The European trials dominating the Cochrane review enrolled patients already engaged in detoxification programs — a population with higher treatment motivation [4]✓ Verified knowledgeKampman et al. (2011) — Double blind placebo.
• When the drug was started. Chick et al. initiated acamprosate a median of 24 days post-detoxification, with 32% of patients already having relapsed before the drug was even started [8]✓ Verified knowledgeChick et al. (2000) — United kingdom multicentre. Acamprosate's mechanism is most relevant in the early post-detox window — not in people who have already returned to drinking.
• Treatment goal. Mason et al. confirmed efficacy only in the subgroup with a baseline goal of complete abstinence [9]✓ Verified knowledgeMason et al. (2006) — Effect oral acamprosate. Acamprosate is an abstinence-maintenance drug, not a harm-reduction drug, and the evidence reflects that [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking.
• Psychosocial support. The European NEAT program showed acamprosate's benefit held regardless of the type of psychosocial support provided [10]✓ Verified knowledgePelc et al. (2002) — European neat program — but all patients received some structured support alongside the medication.

The bottom line: acamprosate is most likely to benefit people who are recently detoxified and abstinent at treatment initiation, explicitly motivated toward complete abstinence, and receiving structured support alongside pharmacotherapy [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking [9]✓ Verified knowledgeMason et al. (2006) — Effect oral acamprosate.

Acamprosate vs. naltrexone: which one fits your situation?

These two medications are not interchangeable. Conflating them leads to mismatched prescribing. Here's how they compare across the dimensions that matter most clinically:

The Maisel et al. meta-analysis provides the clearest comparative picture: acamprosate has a larger effect size for abstinence maintenance, while naltrexone is superior for reducing heavy drinking days and craving [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking. These aren't competing drugs — they're complementary tools for different clinical scenarios.

For someone who has completed detox, is committed to complete abstinence, and has significant liver disease, acamprosate is the preferred agent. For someone still drinking whose goal is reducing heavy drinking days, naltrexone's evidence profile is stronger. Naltrexone has more total trials and once-daily dosing options (including injectable extended-release), which often translates into prescribing preference — but that preference isn't always matched to the patient's actual clinical profile. You can also compare both to [11]✓ Verified knowledgedisulfiram(/treatment/medication/disulfiram/), which works through a completely different deterrent mechanism.

What does dosing look like in real life?

The standard acamprosate dose is 666 mg (two 333-mg tablets) taken three times daily — with breakfast, lunch, and dinner — for a total of 1,998 mg per day [12]✓ Verified knowledgeMaisel et al. (2013) — Meta analysis naltrexone [13]✓ Verified knowledgeKim et al. (2018) — Practical outpatient pharmacotherapy. Consistent adherence to this TID schedule matters for efficacy, since missing doses can undermine the drug's ability to maintain stable glutamate modulation [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking.

One clinically important adjustment: people weighing less than 60 kg receive a reduced dose of 1,332 mg/day, while those weighing 60 kg or more receive the full 1,998 mg/day [13]✓ Verified knowledgeKim et al. (2018) — Practical outpatient pharmacotherapy. This weight-based consideration is underemphasized in many prescribing conversations.

Renal function is the critical dosing variable. Because acamprosate is renally cleared with no hepatic metabolism, kidney function directly determines drug exposure. Renal function should be assessed before initiation and monitored during treatment — particularly in older adults and anyone with conditions that affect kidney function. Dose adjustment is required in renal impairment, and severe kidney disease is a contraindication. Specific eGFR-stratified dosing thresholds require consultation with current prescribing guidelines [14]✓ Verified knowledgeGreen et al. (2023) — Closing care gap.

The TID schedule is one of acamprosate's most significant real-world limitations. Remembering medication three times a day while managing work, family, and early recovery is genuinely hard. This is worth discussing openly before someone starts the medication — not as a reason to avoid it, but as something to plan around.

Why does liver disease change the calculation?

This is where acamprosate's pharmacokinetic profile becomes most clinically important. Because it's renally cleared with no hepatic metabolism, it can be used without dosage adjustment in patients with mild-to-moderate hepatic impairment [14]✓ Verified knowledgeGreen et al. (2023) — Closing care gap. For people managing alcohol-associated liver disease — precisely the population hepatologists most frequently see — this makes acamprosate the pharmacologically preferred AUD medication.

Naltrexone carries hepatotoxicity concerns that complicate its use in patients with significant liver disease. Acamprosate sidesteps that concern entirely.

Real-world data in advanced liver disease introduce important nuance, though. A retrospective case-control study by Oldroyd et al. examined acamprosate use specifically in patients with cirrhosis and/or alcohol-associated hepatitis. After propensity score matching (n = 53 per group), acamprosate prescription was associated with significantly higher readmission rates at 1 year (85% vs. 57%, p < 0.001), with no statistically significant differences in abstinence rates or mortality [15]✓ Verified knowledgeOldroyd et al. (2024) — Real world analysis. That sounds alarming — but the patients prescribed acamprosate consumed substantially more alcohol at baseline than the comparison group [15]✓ Verified knowledgeOldroyd et al. (2024) — Real world analysis. The drug was being given to sicker patients with more severe alcohol use disorder. The higher readmission rate likely reflects greater disease severity in the treated group, not drug-induced harm.

One important gap: there is currently no strong evidence base specifically addressing acamprosate outcomes in patients with decompensated cirrhosis combined with concurrent renal dysfunction — the scenario where both the hepatic safety advantage and the renal contraindication are simultaneously in play. This is the highest-stakes clinical question, and it remains unanswered.

What are the side effects?

Acamprosate has an excellent overall safety profile. The Rösner Cochrane review — the largest synthesis of safety data available — found that diarrhea was the only adverse effect occurring significantly more frequently than placebo (risk difference 0.11; NNT for harm 9.09) [4]✓ Verified knowledgeKampman et al. (2011) — Double blind placebo. That's a remarkably clean signal for a medication used in a medically complex population.

The most common side effects include:

• Diarrhea (> 10%): The primary adherence challenge and the most clinically significant side effect [4]✓ Verified knowledgeKampman et al. (2011) — Double blind placebo.
• Nausea, abdominal pain: Gastrointestinal effects are the predominant adverse event class [10]✓ Verified knowledgePelc et al. (2002) — European neat program [3]✓ Verified knowledgeZastrozhin et al. (2019) — Pharmacogenetics alcohol addiction [12]✓ Verified knowledgeMaisel et al. (2013) — Meta analysis naltrexone.
• Insomnia, anxiety: Less common, and may overlap with post-withdrawal symptoms that would be present regardless.

There is no hepatotoxicity signal and no cardiac signal. People starting acamprosate should be counseled proactively about diarrhea — it's manageable, often transient, and shouldn't be grounds for stopping the medication without first trying dose timing adjustments or dietary modifications. Stopping acamprosate because of diarrhea removes a medication that may be providing meaningful protection against relapse.

When should acamprosate be started?

Acamprosate is not a treatment for acute alcohol withdrawal. Acute withdrawal — tremor, diaphoresis, seizure risk, autonomic instability — requires benzodiazepines or other GABA-active agents. Acamprosate has no role in that phase. If someone you know is in acute withdrawal, the priority is medical stabilization through alcohol detox before any abstinence-maintenance medication is considered.

Acamprosate's role begins after withdrawal has resolved. The drug targets the post-withdrawal glutamate dysregulation that persists for weeks to months after the last drink and drives early relapse. Initiation is typically appropriate 5–7 or more days after the last drink, once acute withdrawal symptoms have subsided.

The timing principle is supported by comparative trial data: studies that initiated acamprosate in recently detoxified, abstinent patients consistently showed better outcomes than those that started it in patients who were still drinking or had already relapsed post-detoxification [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking [8]✓ Verified knowledgeChick et al. (2000) — United kingdom multicentre. The drug works best when it's started in the window it was designed for.

Does combining acamprosate with naltrexone help more?

Given that the two drugs work through different mechanisms, it's a logical question: does combining them produce additive benefit? The COMBINE Project — the largest U.S. trial of AUD pharmacotherapy — tested this directly [1]✓ Verified knowledgeMandaji et al. (2025) — Combination drugs treatment.

The result: the combination did not significantly outperform either agent alone [1]✓ Verified knowledgeMandaji et al. (2025) — Combination drugs treatment. This finding has shaped clinical practice. The practical guidance is to choose the agent best matched to the patient's clinical profile and treatment goals. Combination therapy is not supported as a standard approach by the current evidence base.

A separate case series examined sodium oxybate plus acamprosate in 48 patients with AUD, finding 70.8% maintained continuous abstinence at 3 months [16]✓ Verified knowledgeCaputo et al. (2025) — Sodium oxybate acamprosate. That's a striking figure — but it's an uncontrolled, single-arm case series without a comparator arm. Outcomes can't be attributed to acamprosate specifically, and this evidence doesn't approach the quality of RCT data [16]✓ Verified knowledgeCaputo et al. (2025) — Sodium oxybate acamprosate.

Why is acamprosate so underused?

AUD is one of the most undertreated medical conditions in the United States, and acamprosate is one of the most underused FDA-approved treatments within that already undertreated condition. Understanding why matters for anyone trying to access it or advocate for it.

• TID dosing burden. Three-times-daily dosing is demanding in early recovery. The ADAM trial — an RCT of 739 participants — found that Medication Management plus Contingency Management improved acamprosate adherence by 10.6 percentage points (95% CI 1.6–19.6%) over standard support alone, and was cost-effective [17]✓ Verified knowledgeDonoghue et al. (2023) — Adjunctive medication management. Adherence isn't fixed — it responds to structured support.
• Diarrhea. The most common side effect is also the most likely to prompt early discontinuation without proactive counseling at the start.
• Insurance coverage variability. Coverage varies substantially across payers, and cost can be a real barrier — though systematic data on formulary coverage and prior authorization requirements for acamprosate in the U.S. remain limited.
• Clinician default to naltrexone. Naltrexone has more total trials, once-daily dosing options, and broader name recognition. These practical advantages often translate into prescribing preference even in patients where acamprosate's profile is more appropriate.

One finding worth highlighting: a pooled analysis of 1,485 patients found that acamprosate efficacy was not differentially associated with physiological dependence severity, family history, age of onset, anxiety, craving, or gender [18]✓ Verified knowledgeMellinger et al. (2023) — Management alcohol use. The drug doesn't require a narrow patient phenotype to work. The main selection criteria are clinical: post-detoxification status, abstinence goal, and preserved renal function.

Who needs special consideration?

Renal impairment

Renal function is the single most important clinical variable for acamprosate dosing. Because the drug is renally cleared with no hepatic metabolism, kidney function directly determines drug exposure. Renal function should be assessed before initiation and monitored during treatment, particularly in older adults and those with comorbid conditions affecting kidney function. Age-related decline in glomerular filtration rate means a patient who starts acamprosate with adequate renal function may develop impairment over time, warranting periodic reassessment.

Hepatic impairment

Acamprosate is the preferred AUD pharmacotherapy in patients with hepatic impairment and can be used without dosage adjustment in mild-to-moderate hepatic impairment [14]✓ Verified knowledgeGreen et al. (2023) — Closing care gap. The key caveat: patients with advanced liver disease often have concurrent renal dysfunction. When both are present, the renal contraindication takes precedence, and the clinical decision becomes more complex.

Pregnancy

Acamprosate is classified as Category C — animal studies have shown adverse fetal effects, but there are no adequate well-controlled studies in pregnant women. The risk-benefit decision in pregnancy requires individualized clinical judgment and specialist consultation.

Comorbid psychiatric conditions

There is some data on acamprosate use in patients with comorbid conditions including schizophrenia spectrum disorders and depression [19]✓ Verified knowledgeRalevski et al. (2011) — Treatment acamprosate patients [20]✓ Verified knowledgeLejoyeux et al. (2011) — Alcohol use disorders, though this remains an area where additional evidence would strengthen clinical guidance.

What questions does the research still not answer?

Honest acknowledgment of evidence gaps matters — both for clinical decision-making and for understanding where the field needs to go [14]✓ Verified knowledgeGreen et al. (2023) — Closing care gap [15]✓ Verified knowledgeOldroyd et al. (2024) — Real world analysis.

• Specific renal dosing thresholds. The principle that dose adjustment is required in renal impairment is clear, but eGFR-stratified dosing tables are not well established in the current literature. Clinicians need specific CrCl cutoffs, not just the general principle [14]✓ Verified knowledgeGreen et al. (2023) — Closing care gap.
• Pharmacokinetic basics. Oral bioavailability, half-life, time to steady-state, and the effect of food on absorption are not well characterized in the available evidence — important gaps for pharmacy counseling on missed doses and timing.
• Long-term outcomes beyond 12 months. Most trials follow patients for 6–12 months [4]✓ Verified knowledgeKampman et al. (2011) — Double blind placebo. The natural history of alcohol use disorder is measured in years and decades. Whether acamprosate's benefits persist, attenuate, or require indefinite continuation is not established.
• Optimal treatment duration. Related to the above — when, if ever, it's appropriate to discontinue acamprosate in someone who has maintained abstinence is not addressed by current evidence.
• Diverse demographic populations. The evidence base has limited data on comparative effectiveness across women, racial and ethnic minorities, and other demographic subgroups [21]✓ Verified knowledgeSchick et al. (2020) — Call action systematic. Tailored guidance requires this evidence.
• Adherence intervention scalability. The ADAM trial showed Contingency Management improves adherence [17]✓ Verified knowledgeDonoghue et al. (2023) — Adjunctive medication management, but whether this can be implemented at scale in primary care, alcohol rehab, or telehealth settings remains unanswered.

Acamprosate is an underused, evidence-supported medication for a condition that causes enormous suffering and is dramatically undertreated. Its mechanism is specific and well-characterized: it stabilizes glutamate hyperactivity in the post-withdrawal brain, reducing the neurochemical drive toward early relapse. For the right person — recently detoxified, motivated toward complete abstinence, with preserved renal function — it is a first-line option supported by some of the strongest meta-analytic evidence in AUD pharmacotherapy [4]✓ Verified knowledgeKampman et al. (2011) — Double blind placebo [5]✓ Verified knowledgeGueorguieva et al. (2011) — Baseline trajectories drinking. The barrier to its use isn't the evidence. It's awareness, access, and the clinical infrastructure to support adherence to a three-times-daily regimen in people navigating one of the most challenging recoveries in medicine.